type 1 diabetes and glp-1 SGLT2i RA therapy in and reno-vascular outcomes: a real-world study | Diabetologia Improved Heart and Kidney Outcomes

GLP-1RA therapy could provide a special advantage to patients with multiple risk factors for cardiometabolic diseases such as obesity, hypertension, dyslipidemia and documented atherosclerotic cardiovascular disease

We're #1 for a reason We have been leading the way in functional medicine for 37 years and counting.

Cancer patients produce many inflammatory cytokines [8, 9], such as tumor necrosis factor-alpha (TNF-) [10, 11], proteolysis-inducing factor (PIF), interleukin-1 (IL-1) [9, 12], and interleukin-6 (IL-6) [8, 13]

Strbe et al., 2021) and as a prototypic cytoprotective peptide (for review, see Sikiric et al., 1993a

Nutrition and body composition guidance are built into the visit, because the medication is one part of the plan rather than the whole plan

[DOI] [PMC free article] [PubMed] [Google Scholar] 10.Swann R, McPhail S, Witt J, et al